Back

Boehringer Ingelheim Expands Patient Co-Creation and AI in Clinical Trials

lite News Desk 2 min read

At a glance

  • Boehringer Ingelheim states all clinical trial designs are co-created with patients and trial site staff
  • The company uses digital twins and generative AI to accelerate trial processes
  • A first-in-human oncology study moved from patient dosing to data submission in two years and four months

Boehringer Ingelheim has implemented new approaches in clinical trial design, focusing on collaboration with patients and the use of artificial intelligence tools. These changes are intended to streamline trial operations and enhance participation.

Lykke Hinsch Gylvin, Chief Medical Officer and Head of Global Medicine at Boehringer Ingelheim, stated that all of the company's clinical trial designs are developed in partnership with patients and trial site staff. She also said that more than 90% of trials involve co-creation with patients, caregivers, and trial sites, reflecting an ongoing commitment to this approach.

According to Gylvin, co-creation with patients is associated with faster registration, more efficient trial processes, and endpoints that are more meaningful to participants. She indicated that this model also reduces the burden on participants and encourages broader inclusion in clinical studies.

The company has incorporated advanced digital tools, including digital twins and generative AI, to further accelerate trial design and operations. Gylvin described these technologies as contributing to the feasibility of trials by reducing the number of patients required and simplifying procedures for participants.

What the numbers show

  • 100% of Boehringer Ingelheim’s clinical trial designs are co-created with patients and trial site staff
  • More than 90% of trials involve co-creation with patients, caregivers, and trial sites
  • A first-in-human oncology study progressed from first patient dosing in August 2022 to data submission in December 2024

Gylvin reported that the use of digital twins has allowed Boehringer Ingelheim to reduce the number of participants needed in clinical studies. This approach is intended to improve the feasibility of trials and decrease the demands placed on individuals taking part.

In a McKinsey podcast published in October 2025, Gylvin discussed the integration of generative AI and digital twins into the company’s clinical research processes. She stated that these tools are being used to accelerate the design and execution of trials across the organization.

Boehringer Ingelheim has applied these innovations in recent studies, including a first-in-human oncology trial that moved from initial patient dosing in August 2022 to data submission by December 2024. This timeline demonstrates the company’s efforts to shorten the duration of clinical research phases.

The company’s approach centers on ongoing collaboration with patients, caregivers, and trial sites, as well as the adoption of digital technologies to improve trial efficiency. These measures are designed to support more inclusive and manageable clinical studies.

* This article is based on publicly available information at the time of writing.

Sources and further reading

Note: This section is not provided in the feeds.

Related Articles

  1. A statement outlines new features for data security management, according to reports. The enhancements aim to bolster protection against risks.

  2. A report highlights that AI-specific attacks frequently bypass conventional detection methods, according to industry analysis.

  3. Ecraid will enhance pandemic preparedness with over 2,000 research sites across Europe, supporting the BE READY NOW initiative starting January 2026.

  4. EC-Council introduced four AI certifications in Paris, aligning with France's national AI strategy and the €700 million France 2030 education plan.

  5. Ten semiconductor projects across six Indian states have been approved, with investments exceeding ₹1.6 trillion by late 2025, according to reports.

More on Health

  1. Certain supplements can affect blood sugar levels in diabetes patients. Most are not FDA-approved, raising safety concerns, according to experts.

  2. India's mango production reached 26.3 million tonnes. Yield losses from unseasonal rainfall have affected up to 80% in some regions, reports say.

  3. Citizens Advice's 2024/25 report details rising debt and eviction cases, using client issues to inform policy research, according to the organization.

  4. Pacific University's Public Health Club, led by Autumn Mann, gained visibility after a feature in the Pacific Index on February 21, 2026.